Drug intelligence / Profile preview

promethazine + phenylephrine + codeine

Development stage
Approved
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Promethazine + phenylephrine + codeine is an oral combination drug consisting of **promethazine** (a first-generation antihistamine of the phenothiazine class and an H1 receptor antagonist), **phenylephrine** (a sympathomimetic decongestant and alpha-1 adrenergic receptor agonist), and **codeine** (an opioid analgesic and antitussive agent). This formulation is indicated for the temporary relief of cough, nasal congestion, runny nose, sneezing, and related symptoms caused by allergies or the common cold. Promethazine reduces allergic symptoms by blocking H1 histamine receptors; phenylephrine constricts nasal blood vessels via alpha-1 adrenergic receptor activation to relieve congestion; codeine acts as a mu-opioid receptor agonist in the central nervous system to suppress the cough reflex[1][3][7][11][12].

Brand names
Promethazine VC with CodeinePrometh VC with CodeinePentazine VC with CodeinePhenergan VC with Codeine
Other names
promethazine/phenylephrine/codeine
02

Targets

ADRA1A (α1A)MOR (Mu opioid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on promethazine + phenylephrine + codeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on promethazine + phenylephrine + codeine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call